Single-cell characterization of step-wise acquisition of carboplatin resistance in ovarian cancer

Alexander T Wenzel1,2, Devora Champa3,4, Hrishi Venkatesh5,6

  • 1UC San Diego Bioinformatics and Systems Biology Graduate Program, San Diego, CA, USA.

Insights

Acquired resistance to carboplatin chemotherapy shows significant cell-to-cell variability. Understanding proliferative and quiescent cell states is key to overcoming drug resistance and improving treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genomics

Background:

  • The mechanisms of acquired resistance to carboplatin chemotherapy are not well understood.
  • In vitro studies often yield inconsistent findings regarding carboplatin resistance.
  • Understanding cellular heterogeneity is crucial for effective cancer treatment.

Purpose of the Study:

  • To investigate the molecular basis of acquired resistance to carboplatin.
  • To explore transcriptional heterogeneity in isogenic clones developing resistance.
  • To evaluate the role of cell cycle phases (proliferative and quiescent) in carboplatin resistance.

Main Methods:

  • Utilized gene-expression data from 26,772 single cells across four resistant clones and two treatment steps.
  • Employed virtual synchronization to analyze Hallmark gene set activity in proliferative (P) and quiescent (Q) phases.
  • Compared transcriptional profiles of resistant clones at different stages of treatment.

Main Results:

  • Identified two key behaviors associated with carboplatin resistance: broad gene repression in the P phase and prevalent gene induction in the Q phase.
  • Observed clone-specific induction of IFNα response in P phase or Wnt-signaling in Q phase.
  • Highlighted significant transcriptional heterogeneity despite similar resistance levels across clones.

Conclusions:

  • Proposed a model of 'resistance hysteresis' where alterations in P and Q phase states influence drug response dynamics.
  • Emphasized the need for precise single-cell state monitoring to optimize chemotherapy schedules and combinations.
  • Suggests that targeting specific cell states may overcome carboplatin resistance.